As per NAVADHI Market Research, the global pharmaceutical industry [2] will we worth USD 1.57 trillion by 2023.
Gilead Sciences, Inc. (Gilead) is a U.S. based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead’s primary areas of focus include HIV/AIDS, liver diseases, hematology/oncology and inflammation/respiratory diseases.
Gilead Sciences registered profit in the fourth quarter from a loss last year, helped by a push in income taxes provision.
Company's 2018 Revenue declined 2.6% to USD 5.8 billion. The results reflected by lower product sales in Europe and in other regions. Chronic hepatitis C virus franchise sales plunged 50.8% due to lower average selling price and lower sales volume of Harvoni and Epclusa across all major markets as a result of increased generic competition and the lower patient engagement.
For the fourth quarter, R&D expenses increased by 69.6% Y-O-Y. This was primarily due to an impairment charge related to in-process R&D for multiple myeloma treating program, up-front collaboration expenses and higher investments to support the growth of Gilead’s business following the acquisition of Kite.
Spanning over 30 pages and 18 exhibits, “Gilead Sciences, Inc. - Company Snapshot & SWOT Analysis” report provides value chain analysis, financial performance, business strategy and SWOT analysis for company.
Gilead Sciences, Inc.
*If Applicable.